المؤلفون: А.А. Кучай, А.Н. Липин, Н.Р. Карелина, Н.Н. Груздев, К.А. Атмадзас, Л.Ю. Артюх, О.Ю. Смирнова, А.В. Зайцева

المصدر: Российские биомедицинские исследования, Vol 8, Iss 3 (2024)

مصطلحات موضوعية: острая ишемия конечностей, коронавирусная болезнь 2019, низкомолекулярный гепарин, коронавирус-2 с тяжелым острым респираторным синдромом, тромбэктомия, нефракционированный гепарин, Medicine (General), R5-920

وصف الملف: electronic resource

Relation: https://ojs3.gpmu.org/index.php/biomedical-research/article/view/5830; https://doaj.org/toc/2658-6584; https://doaj.org/toc/2658-6576

URL الوصول: https://doaj.org/article/c4a26a4b6b624d018f4e4f92c4149703

المؤلفون: J. Kh. Khizroeva, A. S. Antonova, E. S. Egorova, N. A. Makatsariya, Д. Х. Хизроева, А. С. Антонова, Е. С. Егорова, Н. А. Макацария

المصدر: Obstetrics, Gynecology and Reproduction; Vol 17, No 6 (2023); 792-800 ; Акушерство, Гинекология и Репродукция; Vol 17, No 6 (2023); 792-800 ; 2500-3194 ; 2313-7347

مصطلحات موضوعية: надропарин кальция, assisted reproductive technologies, ART, in vitro fertilization, IVF, low molecular weight heparin, calcium nadroparin, вспомогательные репродуктивные технологии, ВРТ, экстракорпоральное оплодотворение, ЭКО, низкомолекулярный гепарин

وصف الملف: application/pdf

Relation: https://www.gynecology.su/jour/article/view/1870/1165; Mascarenhas M.N., Flaxman S.R., Boerma T. et al. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med. 2012;9(12):e1001356. https://doi.org/10.1371/journal.pmed.1001356.; Коротченко О.Е., Гвоздева А.Д., Сыркашева А.Г. Исходы программ вспомогательных репродуктивных технологий у пациенток с привычным невынашиванием беременности в анамнезе. Гинекология. 2017;19(6):43–5. https://doi.org/10.26442/2079-5696_19.6.43-45.; Sunderam S., Kissin D.M., Crawford S.B. et al. Assisted Reproductive Technology Surveillance – United States, 2015. MMWR Surveill Summ. 2018;67(3):1–28. https://doi.org/10.15585/mmwr.ss6703a1.; Choe J., Shanks A.L. In Vitro Fertilization. [Updated 2023 Sep 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023. Режим доступа: https://www.ncbi.nlm.nih.gov/books/NBK562266/. [Дата обращения: 20.11.2023].; Di Micco P., Russo V., Mastroiacovo D. et al. In vitro fertilization procedures with embryo transfer and their association with thrombophilia, thrombosis and early antithrombotic treatments. J Blood Med. 2020;11:185–90. https://doi.org/10.2147/JBM.S248988.; Grandone E., Di Micco P.P., Villani M. et al.; RIETE Investigators. Venous thromboembolism in women undergoing assisted reproductive technologies: data from the RIETE Registry. Thromb Haemost. 2018;118(11):1962–8. https://doi.org/10.1055/s-0038-1673402.; D’Uva M., Di Micco P., Strina I.et al. Etiology of hypercoagulable state in women with recurrent fetal loss without other causes of miscarriage from Southern Italy: new clinical target for antithrombotic therapy. Biologics. 2008;2(4):897–902. https://doi.org/10.2147/btt.s3852.; Brenner B., Blumenfeld Z. Thrombophilia and fetal loss. Blood Rev. 1997;11(2):72–9. https://doi.org/10.1016/s0268-960x(97)90013-8.; Henriksson P., Westerlund E., Wallen H. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation: cross sectional study. BMJ. 2013;346:e8632. https://doi.org/10.1136/bmj.e8632.; Грандоне Э. Риск тромбозов и экстракорпоральное оплодотворение. Акушерство, Гинекология и Репродукция. 2022;16(1):90–5. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.286.; Hansen A.T., Kesmodel U.S., Juul S., Hvas A.M. Increased venous thrombosis incidence in pregnancies after in vitro fertilization. Hum Reprod. 2014;29(3):611–7. https://doi.org/10.1093/humrep/det458.; Olausson N., Discacciati A., Nyman A. et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilization with fresh respectively frozen-thawed embryo transfer: Nationwide cohort study. J Thromb Haemost. 2020;18(8):1965–73. https://doi.org/10.1111/jth.14840.; Ironside E.C., Hotchen A.J. Ovarian hyperstimulation syndrome, the master of disguise? Case Rep Emerg Med. 2015;2015:510815. https://doi.org/10.1155/2015/510815.; Fang L., Li Y., Wang S. et al. TGF-β1 induces VEGF expression in human granulosa-lutein cells: a potential mechanism for the pathogenesis of ovarian hyperstimulation syndrome. Exp Mol Med. 2020;52(3):450–60. https://doi.org/10.1038/s12276-020-0396-y.; Rizk B., Aboulghar M., Smitz J., Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update. 1997;3(3):255–66. https://doi.org/10.1093/humupd/3.3.255.; Scotti L., Abramovich D., Pascuali N. et al. Local VEGF inhibition prevents ovarian alterations associated with ovarian hyperstimulation syndrome. J Steroid Biochem Mol Biol. 2014;144 Pt B:392–401. https://doi.org/10.1016/j.jsbmb.2014.08.013.; Gómez R., Soares S.R., Busso C. et al. Physiology and pathology of ovarian hyperstimulation syndrome. Semin Reprod Med. 2010;28(6):448– 57. https://doi.org/10.1055/s-0030-1265670.; Клинические рекомендации – Синдром гиперстимуляции яичников – 2021-2022-2023 (02.09.2021). М.: Министерство здравоохранения Российской Федерации, 2021. 32 c. Режим доступа: http://disuria.ru/_ld/11/1146_kr21N98p1MZ.pdf. [Дата обращения: 20.11.2023].; Khizroeva J., Makatsariya A., Bitsadze V. et al. In vitro fertilization outcomes in women with antiphospholipid antibodies circulation. J Matern Fetal Neonatal Med. 2020;33(12):1988–93. https://doi.org/10.1080/14767058.2018.1535586.; Клинические рекомендации. Венозные осложнения во время беременности и в послеродовом периоде. Акушерская тромбоэмболия. М.: Министерство здравоохранения Российской Федерации, 2022. 99 c. Режим доступа: https://gkb1.chitazdrav.ru/node/9144. [Дата обращения: 20.11.2023].; Greer I.A., Nelson Piercy C. Low molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. 2005;106(2):401–7. https://doi.org/10.1182/blood-2005-02-0626.; Шмаков Р.Г., Вавилова Т.В, Николаева М.Г. и др. Краткие алгоритмы диагностики, профилактики и лечения венозных тромбоэмболических осложнений во время беременности. Акушерство и гинекология. 2022;12 (приложение):4–12.; Bates S.M., Greer I.A., Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S–e736S. https://doi.org/10.1378/chest.11-2300.; Bates S.M., Middeldorp S., Rodger M. et al. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):92–128. https://doi.org/10.1007/s11239-015-1309-0.; Chan W.S., Rey E., Kent N.E.; VTE in Pregnancy Guideline Working Group; Society of Obstetricians and Gynecologists of Canada. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can. 2014;36(6):527–53. https://doi.org/10.1016/s17012163(15)30569-7.; American College of Obstetricians and Gynecologists' Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 197: Inherited thrombophilias in pregnancy. Obstet Gynecol. 2018;132(1):e18–e34. https://doi.org/10.1097/AOG.0000000000002703.; https://www.gynecology.su/jour/article/view/1870

الاتاحة: https://www.gynecology.su/jour/article/view/1870
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2023.467

المؤلفون: A. V. Samorodov, K. N. Zolotukhin

المصدر: Креативная хирургия и онкология, Vol 10, Iss 2, Pp 137-142 (2020)

مصطلحات موضوعية: тяжелый острый респираторный синдром, коронавирус, гемостаз, болезни коронарных артерий, стенты, антикоагулянты, венозный тромбоз, тромбоэмболия, двс-синдром, низкомолекулярный гепарин, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

Relation: https://www.surgonco.ru/jour/article/view/491; https://doaj.org/toc/2307-0501; https://doaj.org/toc/2076-3093

URL الوصول: https://doaj.org/article/e23f05ee362e491b80ea66f690ec1693

المؤلفون: E. A. Orudzhova, V. O. Bitsadze, M. V. Tretyakova, D. A. Doronicheva, F. Yakubova, Э. А. Оруджова, В. О. Бицадзе, М. В. Третьякова, Д. А. Дороничева, Ф. Якубова

المصدر: Obstetrics, Gynecology and Reproduction; Vol 16, No 2 (2022); 134-142 ; Акушерство, Гинекология и Репродукция; Vol 16, No 2 (2022); 134-142 ; 2500-3194 ; 2313-7347

مصطلحات موضوعية: АФС, FGR, prophylaxis, low molecular weight heparin, LMWH, acetylsalicylic acid, ASA, thrombophilia, antiphospholipid antibodies, APA, antiphospholipid syndrome, APS, ЗРП, профилактика, низкомолекулярный гепарин, НМГ, ацетилсалициловая кислота, АСК, тромбофилия, антифосфолипидные антитела, АФА, антифосфолипидный синдром

وصف الملف: application/pdf

Relation: https://www.gynecology.su/jour/article/view/1308/1001; Brosens I., Pijnenborg R., Vercruysse L., Romero R. The "Great Obstetrical Syndromes" are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011;204(3):193–201. https://doi.org/10.1016/j.ajog.2010.08.009.; Gardosi J., Madurasinghe V., Williams M. et al. Maternal and fetal risk factors for stillbirth:populationbasedstudy. BMJ. 2013;346:f108. https://doi.org/10.1136/bmj.f108.; Malacova E., Regan A., Nassar N. et al. Risk of stillbirth, preterm delivery, and fetal growth restriction following exposure in a previous birth: systematic review and meta-analysis. BJOG. 2018;125(2):183–92. https://doi.org/10.1111/1471-0528.14906.; Abou-Nassar K., Carrier M., Ramsay Т., Rodger М.А. The association between antiphospholipid antibodies and placenta-mediated complications: а systematic review and meta-analysis. Thromb Res. 2011;128(1):77–85. https://doi.org/10.1016/j.thromres.2011.02.006.; Гри Ж.К., Макацария А.Д., Бицадзе В.О. и др. Антифосфолипидный синдром и беременность. Акушерство и гинекология. 2018;(10):5–11. https://doi.org/10.18565/aig.2018.10.5-11.; Saccone G., Berghella V., Maruotti G.M. et al. Antiphospholipid antibody profile based obstetric outcomes of primary antiphospholipid syndrome: the PREGNANTS study. Am J Obstet Gynecol. 2017;216(5):525.e1–525.e12. https://doi.org/10.1016/j.ajog.2017.01.026.; Polzin W.J., Kopelman J.N., Robinson R.D. et al. The association of antiphospholipid antibodies with pregnancies complicated by fetal growth restriction. Obstet Gynecol. 1991;78(6):1108–11.; Schjetlein R., Moe N., Wisloff F. et al. Preeclampsia and fetal growth retardation: is there an association with antiphospholipid antibodies? Hypertension in Pregnancy. 2009;17(1):81–92. https://doi.org/10.3109/10641959809072240.; Spegiorin L.C.J.F., Galão E.A., De Godoy J.M.P. et al. Antiphospholipid antibodies and growth retardation in intrauterine development. Prague Med Rep. 2007;108(2):185–90.; Оруджова Е.А. Антифосфолипидные антитела, генетическая тромбофилия и задержка роста плода. Акушерство, Гинекология и Репродукция. 2021;15(6):695–704. https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.278.; Heilmann L., von Tempelhoff G.-F., Pollow K. Antiphospholipid syndrome in obstetrics. Clin Appl Thromb Hemost. 2002;9(2):143–50. https://doi.org/10.1177/107602960300900209.; https://www.gynecology.su/jour/article/view/1308

الاتاحة: https://www.gynecology.su/jour/article/view/1308
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2022.309

المؤلفون: K. Sultangadzhieva G., N. Babaeva N., E. Egorova S., J. Khizroeva Kh., M. Sultangadzhiev G., Х. Султангаджиева Г., Н. Бабаева Н., Е. Егорова С., Д. Хизроева Х., М. Султангаджиев Г.

المصدر: Obstetrics, Gynecology and Reproduction; Vol 15, No 5 (2021); 548-561 ; Акушерство, Гинекология и Репродукция; Vol 15, No 5 (2021); 548-561 ; 2500-3194 ; 2313-7347

مصطلحات موضوعية: retrochorial hematoma, RH, bleedings in early pregnancy, antiphospholipid antibodies, АРА, bacterial viral infections during pregnancy, plasminogen activator inhibitor, miscarriage, low molecular weight heparin, LMWH, antifibrinolytics, ретрохориальная гематома, РГ, кровотечения на ранних сроках беременности, потери беременности, антифосфолипидные антитела, АФА, бактериально-вирусные инфекции при беременности, ингибитор активатора плазминогена, низкомолекулярный гепарин, НМГ, антифибринолитики

وصف الملف: application/pdf

Relation: https://www.gynecology.su/jour/article/view/1132/958; Elsasser D.A., Ananth C.V., Prasad V., Vintzileos A.M.; New JerseyPlacental Abruption Study Investigators. Diagnosis of placental abruption: relationship between clinical and histopathological findings. Eur J Obstet Gynecol Reprod Biol. 2010;148(2):125–30. https://doi.org/10.1016/j.ejogrb.2009.10.005.; Mantoni M., Pedersen J.F. Intrauterine hematoma: an ultrasonic study of threatened abortion. BJOG. 1981;88:47–51. https://doi.org/10.1111/j.1471-0528.1981.tb00936.x.; Jouppila P. Clinical consequences after ultrasonic diagnosis of intrauterine hematoma in threatened abortion. J Clin Ultrasound. 1985;13(2):107–11. https://doi.org/10.1002/jcu.1870130205.; Pearlstone M., Baxi L. Subchorionic hematoma: а review. Obstet Gynecol Surv. 1993;48(2):65–8.; Kurjak A., Schulman H., Zudenigo D. et al. Subchorionic hematomas in early pregnancy: clinical outcome and blood flow patterns. J Matern Fetal Med. 1996;5(1):41–4. https://doi.org/0.1002/(SICI)1520-6661(199601/02)5:13.0.CO;2-Q.; Seki H., Kuromaki K., Takeda S., Kinoshita K. Persistent subchorionic hematoma with clinical symptoms until delivery. Int J Gynaecol Obstet. 1998;63(2):123–8. https://doi.org/10.1016/s0020-7292(98)00153-2.; Sharma G., Kalish R., Chasen S. Prognostic factors associated with antenatal subchorionic echolucencies. Am J Obstet Gynecol. 2003;189(4):994–6. https://doi.org/10.1067/s0002-9378(03)00823-8.; Şükür Y.E., Göç G., Köse O. et al. The effects of subchorionic hematoma on pregnancy outcome in patients with threatened abortion. J Turk Ger Gynecol Assoc. 2014;15(4):239–42.; Peitsidis P., Kadir R.A. Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert Opin Pharmacother. 2011;12(4):503– 16. https://doi.org/10.1517/14656566.2011.545818.; Wang D., Luo Z.Y., Yu Z.P. et al. The antifibrinolytic and anti-inflammatory effects of multiple doses of oral tranexamic acid in total knee arthroplasty patients: a randomized controlled trial. J Thromb Haemost. 2018;16(12):2442–53. https://doi.org/10.1111/jth.14316.; Бицадзе В.О., Макацария А.Д. Применение низкомолекулярных гепаринов в акушерской практике. РМЖ. 2000;(18):772–7.; Хизроева Д.Х. Антифосфолипидный синдром и неудачи экстракорпорального оплодотворения. Практическая медицина. 2013;(6):154–60.; De Sancho M.T., Khalid S., Christos P.J. Outcomes in women receiving low-molecular-weight heparin during pregnancy. Blood Coagul Fibrinolysis. 2012;23(8):751–55. https://doi.org/10.1097/MBC.0b013e328358e92c.; Макацария А.Д., Бицадзе В.О. Антифосфолипидный синдром, генетические тромбофилии в патогенезе основных форм акушерской патологии. РМЖ. 2006;(0):2–10.; Макацария А.Д, Серов В.Н., Гри Ж.К. и др. Катастрофический антифосфолипидный синдром и тромбозы. Акушерство и гинекология. 2019;(9):5–14. https://doi.org/10.18565/aig.2019.9.5-14.; Ye Y., Vattai A., Zhang X. et al. Role of plasminogen activator inhibitor type 1 in pathologies of female reproductive diseases. Int J Mol Sci. 2017;18(8):1651. https://doi.org/10.3390/ijms18081651.; Feng L., Allen T.K., Marinello W.P., Murtha A.P. Infection-induced thrombin production: a potential novel mechanism for preterm premature rupture of membranes (PPROM). Am J Obstet Gynecol. 2018;219(1):101. е1–101.е12. https://doi.org/10.1016/j.ajog.2018.04.014.; https://www.gynecology.su/jour/article/view/1132

الاتاحة: https://www.gynecology.su/jour/article/view/1132
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.227

المؤلفون: S. V. Akinshina, P. K. Genina, V. O. Bitsadze, J. Kh. Khizroeva, V. I. Tsibizova, A. D. Makatsariya, С. В. Акиньшина, П. К. Генина, В. О. Бицадзе, Дж. Х. Хизроева, В. И. Цибизова, А. Д. Макацария

المصدر: Obstetrics, Gynecology and Reproduction; Vol 15, No 4 (2021); 441-450 ; Акушерство, Гинекология и Репродукция; Vol 15, No 4 (2021); 441-450 ; 2500-3194 ; 2313-7347

مصطلحات موضوعية: ривароксабан, pregnancy, low molecular weight heparin, antithrombin III concentrate, rivaroxaban, беременность, низкомолекулярный гепарин, концентрат антитромбина III

وصف الملف: application/pdf

Relation: https://www.gynecology.su/jour/article/view/1072/936; Di Minno M.N., Ambrosino P., Ageno W. et al. Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. Thromb Res. 2015;135(5):923-32. https://doi.org/10.1016/j.thromres.2015.03.010.; Vossen C.Y., Conard J., Fontcuberta J. et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost. 2005;3(3):459-64. https://doi.org/10.1111/j.1538-7836.2005.01197.x.; Lim W., Eikelboom J.W., Ginsberg J.S. Inherited thrombophilia and pregnancy associated venous thromboembolism. BMJ. 2007;334(7607):1318-21. https://doi.org/10.1136/bmj.39205.484572.55.; Wickstrom K., Edelstam G., Lowbeer C.H. et al. Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand J Clin Lab Invest. 2004;64(1):31-40. https://doi.org/10.1080/00365510410003859.; James A.H., Bates S.M., Bauer K.A. et al. Management of hereditary antithrombin deficiency in pregnancy. Thromb Res. 2017;157:41-5. https://doi.org/10.1016/j.thromres.2017.05.017.; Franchi F., Biguzzi E., Martinelli I. et al. Normal reference ranges of antithrombin, protein C and protein S: effect of sex, age and hormonal status. Thromb Res. 2013;132(2):e152-7. https://doi.org/10.1016/j.thromres.2013.07.003.; Folkeringa N., Brouwer J.L., Korteweg F.J. et al. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women. Br J Haematol. 2007;136(4):656-61. https://doi.org/10.1111/j.1365-2141.2006.06480.x.; Mahmoodi B.K., Brouwer J.L., Ten Kate M.K. et al. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J Thromb Haemost. 2010;8(6):1193-200. https://doi.org/10.1111/j.1538-7836.2010.03840.x.; Sabadell J., Casellas M., Alijotas-Reig J. et al. Inherited antithrombin deficiency and pregnancy: maternal and fetal outcomes. Eur J Obstet Gynecol Reprod Biol. 2010;149(1):47-51. https://doi.org/10.1016/j.ejogrb.2009.12.004.; James A.H., Jamison M.G., Brancazio L.R., Myers E.R. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194(5):1311-5. https://doi.org/10.1016/j.ajog.2005.11.008.; James A.H., Konkle B.A., Bauer K.A. Prevention and treatment of venous thromboembolism in pregnancy in patients with hereditary antithrombin deficiency. Int J Womens Health. 2013;5:233-41. https://doi.org/10.2147/IJWH.S43190.; Holbrook A., Schulman S., Witt D.M. et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians EvidenceBased Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S-e184S. https://doi.org/10.1378/chest.11-2295.; Bates S.M., Greer I.A., Middeldorp S. et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S-e736S. https://doi.org/10.1378/chest.11-2300.; Kearon C., Akl E.A., Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-52. https://doi.org/10.1016/j.chest.2015.11.026.; Tiede A., Tait R.C., Shaffer D.W. et al. Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations. Thromb Haemost. 2008;99(3):616-22. https://doi.org/10.1160/TH07-08-0489.; Rheaume M., Weber F., Durand M., Mahone M. Pregnancy-related venous thromboembolism risk in asymptomatic women with antithrombin deficiency: a systematic review. Obstet Gynecol. 2016;127(4):649-56. https://doi.org/10.1097/AOG.0000000000001347.; Pascual C., Munoz C., Huerta A.R. et al. A new case of successful outcome of pregnancy in a carrier of homozygous type II (L99F) antithrombin deficiency. Blood Coagul Fibrinolysis. 2014;25(1):74-6. https://doi.org/10.1097/MBC.0b013e3283646620.; Reducing the risk of venous thromboembolism during pregnancy and the puerperium. Green-top Guideline No. 37a. Royal College of Obstetricians and Gynaecologists, 2015. 40 p. Available at: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37a.pdf.; ACOG Practice Bulletin No. 197: Inherited Thrombophilias in Pregnancy. Obstet Gynecol. 2018;132(1):e18-e34. https://doi.org/10.1097/AOG.0000000000002703.; ACOG Practice Bulletin No. 196: Thromboembolism in Pregnancy. Obstet Gynecol. 2018;132(1):e1-e17. https://doi.org/10.1097/AOG.0000000000002706.; Bates S.M., Rajasekhar A., Middeldorp S. et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv. 201827;2(22):3317-59. https://doi.org/10.1182/bloodadvances.2018024802.; Rogenhofer N., Bohlmann M.K., Beuter-Winkler P. et al. Prevention, management and extent of adverse pregnancy outcomes in women with hereditary antithrombin deficiency. Ann Hematol. 2014;93(3):385-92. https://doi.org/10.1007/s00277-013-1892-0.; Refaei M., Xing L., Lim W. et al. Management of venous thromboembolism in patients with hereditary antithrombin deficiency and pregnancy: case report and review of the literature. Case Rep Hematol. 2017;2017:9261351. https://doi.org/10.1155/2017/9261351.; Skelley J.W., White C.W., Thomason A.R. The use of direct oral anticoagulants in inherited thrombophilia. J Thromb Thrombolysis. 2017;43(1):24-30. https://doi.org/10.1007/s11239-016-1428-2.; Serrao A., Lucani B., Mansour D. et al. Direct oral anticoagulants in patients affected by major congenital thrombophilia. Mediterr J Hematol Infect Dis. 2019;11(1):e2019044. https://doi.org/10.4084/MJHID.2019.044.; https://www.gynecology.su/jour/article/view/1072

الاتاحة: https://www.gynecology.su/jour/article/view/1072
https://doi.org/10.17749/2313-7347/ob.gyn.rep.2021.230

المؤلفون: Makatsariya, A.D., Макацария, А.Д., Mitriuc, D., Mitryuk, D.V.

المصدر: Obstetrics, Gynecology and Reproduction 14 (2) 159-162

مصطلحات موضوعية: SARS-CoV-2, COVID-19, Coronavirus, disseminated intravascular coagulation, DIC, anticoagulant therapy, low molecular weight heparin, LMWH, коронавирус, синдром диссеминированного внутрисосудистого свертывания, ДВС-синдром, антикоагулянтная терапия, низкомолекулярный гепарин, НМГ

وصف الملف: application/pdf

Relation: https://ibn.idsi.md/vizualizare_articol/111048; urn:issn:23137347

الاتاحة: https://ibn.idsi.md/vizualizare_articol/111048
https://doi.org/10.17749/2313-7347.133

المؤلفون: Medved, V. I., Danylkiv, O. O.

المصدر: Actual Problems of Pediatry, Obstetrics and Gynecology; No. 1 (2009) ; Актуальные вопросы педиатрии, акушерства и гинекологии; № 1 (2009) ; Актуальні питання педіатрії, акушерства та гінекології; № 1 (2009) ; 2415-301X ; 2411-4944 ; 10.11603/24116-4944.2009.1

مصطلحات موضوعية: thromboembolic vein complications, pregnancy, low-molecular heparin, тромботические осложнения, беременность, низкомолекулярный гепарин, тромботичні ускладнення, вагітність, низькомолекулярний гепарин

وصف الملف: application/pdf

Relation: https://ojs.tdmu.edu.ua/index.php/act-pit-pediatr/article/view/9655/9313; https://ojs.tdmu.edu.ua/index.php/act-pit-pediatr/article/view/9655; https://repository.tdmu.edu.ua//handle/123456789/14824

الاتاحة: https://repository.tdmu.edu.ua//handle/123456789/14824
https://ojs.tdmu.edu.ua/index.php/act-pit-pediatr/article/view/9655
https://doi.org/10.11603/24116-4944.2009.1.9655

المؤلفون: O. Ostroumova D., I. Goloborodova V., О. Остроумова Д., И. Голобородова В.

المساهمون: The article was published with the financial support of the Pfizer company ., Статья опубликована при финансовой поддержке компании Пфайзер.

المصدر: Rational Pharmacotherapy in Cardiology; Vol 16, No 3 (2020); 404-414 ; Рациональная Фармакотерапия в Кардиологии; Vol 16, No 3 (2020); 404-414 ; 2225-3653 ; 1819-6446

مصطلحات موضوعية: osteoporosis, osteoporetic fracture, atrial fibrillation, venous thromboembolism, anticoagulants, heparin, low molecular weight heparin, warfarin, direct oral anticoagulants, apixaban, остеопороз, остеопоретический перелом, фибрилляция предсердий, венозные тромбоэмболии, антикоагулянты, гепарин, низкомолекулярный гепарин, варфарин, прямые оральные антикоагулянты, апиксабан

وصف الملف: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2225/1993; Piran S., Schulman S. Management of venous thromboembolism: An update. Thromb J. 2016;14:107-15. DOI:10.1186/s12959-016-0107-z.; Granger C.B., Alexander J.H., McMurray J.J., et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-92. DOI:10.1056/NE-JMoa1107039.; Connolly S.J., Eikelboom J., Joyner C., et al. AVERROES Steering Committee Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806-17. DOI:10.1056/NEJMoa1007432.; Hylek E.M., Held C., Alexander J.H., et al. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. J Am Coll Cardiol. 2014;63:2141-7. DOI:10.1016/j.jacc.2014.02.549.; Flaker G.C., Eikelboom J.W., Shestakovska O., et al. Bleeding during treatment with aspirin versus apix-aban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. Stroke. 2012;43:3291-7. DOI:10.1161/STROKEAHA.112.664144.; Brandjes D.P., Heijboer H., Buller H.R., et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1992;327:1485-9. DOI:10.1056/NEJM199211193272103.; Kelman A., Lane N.E. The management of secondary osteoporosis. Best Pract Res Clin Rheumatol. 2005;19:1021-37. DOI:10.1016/j.berh.2005.06.005.; Borgelt L.M., Fixen D.R. Osteoporosis and Osteomalacia. In: Tisdale J.E., Miller D.A., eds. Drug-Induced Diseases: Prevention, Detection, and Management. 3rd ed. Bethesda: American Society of Health-System Pharmacists; 2018: 1119-33.; Jamal S.A., Browner W.S., Bauer D.C., Cummings S.R. Study of Osteoporotic Fractures Research Group. Warfarin use and risk for osteoporosis in elderly women. Ann Intern Med. 1998;128:829-32. DOI:10.7326/0003-4819-128-10-199805150-00006.; Tufano A., Coppola A., Contaldi P., et al. Oral Anticoagulant Drugs and the Risk of Osteoporosis: New Anticoagulants Better than Old? Semin Thromb Hemost. 2015; 41:382-8. DOI:10.1055/s-0034-1543999.; Nelson-Piercy C. Hazards of heparin: Allergy, Heparin-Induced thrombocytopenia and osteoporosis. Baillieres Clin Obstet Gynaecol. 1997;11:489-509. DOI:10.1016/S0950-3552(97)80024-7.; Alban S. Adverse effects of heparin. Handb Exp Pharmacol. 2012;207:211-63. DOI:10.1007/978-3-642-23056-1_10.; Schulman S., Hellgren-Wаngdahl M. Pregnancy, heparin and osteoporosis. Thromb Haemost. 2002;87:180-1.; Barbour L.A., Kick S.D., Steiner J.F., et al. A prospective study of Heparin-Induced osteoporosis in pregnancy using bone densitometry. Am. J. Obstet. Gynecol. 1994;170:862-9. DOI:10.1016/S0002-9378(94)70299-3.; Muir J.M., Andrew M., Hirsh J., et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood. 1996;88:1314-20. DOI:10.1182/blood.V88.4.1314.bloodjournal8841314.; Muir J.M., Hirsh J., Weitz J.I., et al. A histomorphometric comparison of the effects of heparin and Low-Molecular weight heparin on cancellous bone in rats. Blood. 1997;89:3236-42. DOI:10.1182/blood.V89.9.3236.; Shaughnessy S.G., Young E., Deschamps P., Hirsh J. The effects of low molecular weight and standard heparin on calcium loss from fetal rat calvaria. Blood. 1995;86:1368-73. DOI:10.1182/blood.V86.4.1368.bloodjournal8641368.; Handschin A.E., Trentz O.A., Hoerstrup S.P., et al. Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro. Br J Surg. 2005;92:177-83. DOI:10.1002/bjs.4809.; Osip S.L., Butcher M., Young E., et al. Differential effects of heparin and low molecular weight heparin on osteoblastogenesis and adipogenesis in vitro. Thromb Haemost. 2004;92:803-10. DOI:10.1160/TH04-03-0199.; Bhandari M., Hirsh J., Weitz J.I., et al. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost. 1998;80:413-7. DOI:10.1055/s-0037-1615222.; Irie A., Takami M., Kubo H., et al. Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone. 2007;41:165-74. DOI:10.1016/j.bone.2007.04.190.; Melissari E., Parker C.J., Wilson N.V., et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost. 1992;68: 652-6.; Vik A., Brodin E., Sveinbjornsson B., Hansen J.B. Heparin induces mobilization of osteoprotegerin into the circulation. Thromb Haemost. 2007;98:148-54.; Dahlman T.C., Sjoberg H.E., Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol. 1994;170:1315-20. DOI:10.1016/S0002-9378(13)90457-9.; Douketis J.D., Ginsberg J.S., Burrows R.F., et al. The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost. 1996;75:254-7.; Nelson-Piercy C., Letsky E.A., de Swiet M. Low-Molecular weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol. 1997;176:1062-8. DOI:10.1016/S0002-9378(97)70403-4.; Casele H.L., Laifer S.A. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium. J Matern Fetal Med. 2000;9:122-5.; Greer I.A., Nelson-Piercy C. Low-Molecular-Weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: A systematic review of safety and efficacy. Blood. 2005;106:401-7. DOI:10.1182/blood-2005-02-0626.; Lefkou E., Khamashta M., Hampson G., Hunt B.J. Review: Low-Molecular-Weight Heparin-Induced osteoporosis and osteoporotic fractures: A myth or an existing entity? Lupus. 2010;19:3-12. DOI:10.1177/0961203309353171.; Carlin A.J., Farquharson R.G., Quenby S.M., et al. Prospective observational study of bone mineral density during pregnancy: Low molecular weight heparin versus control. Hum Reprod. 2004;19:1211-4. DOI:10.1093/humrep/deh115.; Pettila V., Leinonen P., Markkola A., et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost. 2002;87:182-96. DOI:10.1055/s-0037-1612970.; Tsvetov G., Levy S., Benbassat C., et al. Influence of number of deliveries and total Breast-Feeding time on bone mineral density in premenopausal and young postmenopausal women. Maturitas. 2014;77:249-54. DOI:10.1016/j.maturitas.2013.11.003.; Wawrzynska L., Tomkowski W.Z., Przedlacki J., et al. Changes in bone density during Long-Term administration of Low-Molecular-Weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism. Pathophysiol Haemost Thromb. 2003;33:64-7. DOI:10.1159/000073848.; Bernis C. Mineral bone density variation in hemodialysis patients: Nonfractioned heparin (NFH) versus low molecular weight heparin (LMWH). Nephrol Dial Transplant. 1997;12:1789.; Lai K.N., Ho K., Cheung R.C., et al. Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis. Int J Artif Organs. 2001;24:447-55. DOI:10.1177/039139880102400708.; Serra R., Buffone G., De Franciscis A., et al. Skin grafting followed by low molecular-weight heparin long-term therapy in chronic venous leg ulcers. Ann Vasc Surg. 2012;26:190-7. DOI:10.1016/j.avsg.2011.04.008.; Grassman E.D., Leya F., Fareed J. et al. A randomized trial of the low Molecular-Weight heparin certoparin to prevent restenosis following coronary angioplasty. J Invasive Cardiol. 2001;13:723-8.; Monreal M., Olive A., Lafoz E., del Rio L. Heparins, coumarin, and bone density. Lancet. 1991;338:706. DOI:10.1016/0140-6736(91)91292-3.; Grzegorzewska A.E., Mlot-Michalska M. Low molecular weight heparins and antiplatelet drugs, and bone mineral density in dialysis patients. Adv Perit Dial. 2008;24:125-31.; Pettila V., Kaaja R., Leinonen P., et al. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res. 1999;96:275-82. DOI:10.1016/S0049-3848(99)00110-3.; Dahlman T.C. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol. 1993;168:1265-70. DOI:10.1016/0002-9378(93)90378-V.; Monreal M., Lafoz E., Olive A., et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost. 1994;71:7-11. DOI:10.1055/s-0038-1642376.; Gajic-Veljanoski O., Chai W., Prakesh S., Cheung A.M. Effects of Long-Term Low- Molecular-Weight Heparin on Fractures and Bone Density in Non-Pregnant Adults: A Systematic Review with MetaAnalysis. J Gen Intern Med. 2016;31:947-57. DOI:10.1007/s11606-016-3603-8.; Karsenty G., Olson E.N. Bone and Muscle Endocrine Functions: Unexpected Paradigms of Inter-Organ Communication. Cell. 2016;164:1248-56. DOI:10.1016/j.cell.2016.02.043.; Price P.A., Williamson M.K. Effects of warfarin on bone. Studies on the vitamin K-dependent protein of rat bone. J Biol Chem. 1981;256:12754-9.; Ferriеre K., Rizzoli R. Anticoagulants and osteoporosis [in French]. Rev Med Suisse. 2007;3: 1508-11.; Pearson D.A. Bone health and osteoporosis: The role of vitamin K and potential antagonism by anticoagulants. Nutr Clin Pract. 2007;22:517-44. DOI:10.1177/0115426507022005517.; Vermeer C. Vitamin K: The effect on health beyond coagulation - An overview. Food Nutr Res. 2012;56:5329. DOI:10.3402/fnr.v56i0.5329.; Cranenburg E.C., Schurgers L.J., Vermeer C. Vitamin K: The coagulation vitamin that became omnipotent. Thromb Haemost. 2007;98:120-5. DOI:10.1160/TH07-04-0266.; Szulc P., Arlot M., Chapuy M.C., et al. Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J Bone Miner Res. 1994;9:1591-5. DOI:10.1002/jbmr.5650091012.; Avgeri M., Papadopoulou A., Platokouki H., et al. Assessment of bone mineral density and markers of bone turnover in children under Long-Term oral anticoagulant therapy. J Pediatr Hematol Oncol. 2008;30:592-7. DOI:10.1097/MPH.0b013e31817541a8.; Rezaieyazdi Z., Falsoleiman H., Khajehdaluee M. et al. Reduced bone density in patients on longterm warfarin. Int J Rheum Dis. 2009;12:130-5. DOI:10.1111/j.1756-185X.2009.01395.x.; Caraballo P.J., Heit J.A., Atkinson E.J., et al. Long-Term use of oral anticoagulants and the risk of fracture. Arch Intern Med. 1999;159:1750-6. DOI:10.1001/archinte.159.15.1750.; Gage B.F., Birman-Deych E., Radford M.J., et al. Risk of osteoporotic fracture in elderly patients taking warfarin: Results from the National Registry of Atrial Fibrillation 2. Arch Intern Med. 2006;166:241-6. DOI:10.1001/archinte.166.2.241.; Fiordellisi W., White K., Schweizer M. A Systematic Review and Meta-Analysis of the Association Between Vitamin K Antagonist Use and Fracture. J. Gen. Intern. Med 2019;34:304-11. DOI:10.1007/s11606-018-4758-2.; Gigi R., Salai M., Dolkart O., et al. The effects of direct factor Xa inhibitor (Rivaroxaban) on the human osteoblastic cell line SaOS2. Connect Tissue Res. 2012;53:446-50. DOI:10.3109/03008207.2012.711867.; Somjen D., Katzburg S., Gigi R., et al. Rivaroxaban, a direct inhibitor of the coagulation factor Xa interferes with hormonal-induced physiological modulations in human female osteoblastic cell line SaSO2. J Steroid Biochem Mol Biol. 2013;135:67-70. DOI:10.1016/j.jsbmb.2013.01.006.; Winkler T., Perka C., Matziolis D., Matziolis G. Effect of a direct thrombin inhibitor compared with dalteparin and unfractionated heparin on human osteoblasts. Open Orthop. J 2011;5:52-8. DOI:10.2174/1874325001105010052.; Morishima Y., Kamisato C., Honda Y., et al. The effects of warfarin and edoxaban, an oral direct factor Xa inhibitor, on gammacarboxylated (Gla-osteocalcin) and undercarboxylated osteocalcin (uc-os-teocalcin) in rats. Thromb Res. 2013;131:59-63. DOI:10.1016/j.thromres.2012.08.304.; Solayar G.N., Walsh P.M., Mulhall K.J. The effect of a new direct Factor Xa inhibitor on human osteoblasts: An in-vitro study comparing the effect of rivaroxaban with enoxaparin. BMC Musculoskelet Disord. 2011;12:247. DOI:10.1186/1471-2474-12-247.; Pilge H., Frobel J., Mrotzek S.J. et al. Effects of thromboprophylaxis on mesenchymal stromal cells during osteogenic differentiation: An in-vitro study comparing enoxaparin with rivaroxaban. BMC Musculoskelet. Disord 2016;17:108. DOI:10.1186/s12891-016-0966-2.; Namba S., Yamaoka-Tojo M., Kakizaki R. et al. Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation. Heart Vessels 2017;32:977-82. DOI:10.1007/s00380-017-0950-2.; Abd El Ghafar O.A.M.A., Helal G.K., Abo-Yousef A.M. Apixaban exhibits anti-arthritic effects by inhibiting activated factor X-mediated JAK2/STAT3 and MAPK phosphorylation pathways. Inflam-mopharmacol 2020. DOI:10.1007/s10787-020-00693-8.; Huang H.K., Liu P.P.S., Hsu J.Y et al. Risk of Osteoporosis in Patients ^th Atrial Fibrillation Using NonVitamin K Antagonist Oral Anticoagulants or Warfarin. J Am Heart Assoc 2020;9:e013845. DOI:10.1161/JAHA.119.013845.; Treceno-Lobato C., Jimenez-Serrania M.I., Martinez-Garcia R. et al. New Anticoagulant Agents: Incidence of Adverse Drug Reactions and New Signals Thereof. Semin. Thromb. Hemost 2019;45:196-204.; Lau W.C., Chan E.W., Cheung C.L. et al. Association Between Dabigatran vs Warfarin and Risk of Osteoporotic Fractures Among Patients with Nonvalvular Atrial Fibrillation. JAMA 2017;317:1151-8. DOI:10.1001/jama.2017.1363.; Huang H.-K., Liu P.P.-S., Hsu J.-Y. et al. Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study. European Heart Journal. 2020;0:1-9. DOI:10.1093/eurheartj/ehz952.; https://www.rpcardio.com/jour/article/view/2225

الاتاحة: https://www.rpcardio.com/jour/article/view/2225
https://doi.org/10.20996/1819-6446-2020-06-07

المؤلفون: A. D. Makatsariya, K. N. Grigoreva, M. A. Mingalimov, V. O. Bitsadze, J. Kh. Khizroeva, M. V. Tretyakova, I. Elalamy, A. S. Shkoda, V. B. Nemirovskiy, D. V. Blinov, D. V. Mitryuk, А. Д. Макацария, К. Н. Григорьева, М. А. Мингалимов, В. О. Бицадзе, Д. Х. Хизроева, М. В. Третьякова, И. Элалами, А. С. Шкода, В. Б. Немировский, Д. В. Блинов, Д. В. Митрюк

المصدر: Obstetrics, Gynecology and Reproduction; Vol 14, No 2 (2020); 123-131 ; Акушерство, Гинекология и Репродукция; Vol 14, No 2 (2020); 123-131 ; 2500-3194 ; 2313-7347

مصطلحات موضوعية: НМГ, COVID-19, coronavirus, disseminated intravascular coagulation, DIC, anticoagulant therapy, low molecular weight heparin, LMWH, коронавирус, синдром диссеминированного внутрисосудистого свертывания, ДВС-синдром, антикоагулянтная терапия, низкомолекулярный гепарин

وصف الملف: application/pdf

Relation: https://www.gynecology.su/jour/article/view/633/798; https://www.gynecology.su/jour/article/view/633/799; Novel Coronavirus – China. World Health Organization. January 12, 2020. Available at: https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en. [Accessed: 08.04.2020].; Zhu N., Zhang D., Wang W. et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33. DOI:10.1056/NEJMoa2001017.; Li Q., Guan X., Wu P. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–207. DOI:10.1056/NEJMoa2001316.; Chan J. F., Yuan S., Kok K.H. et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster. Lancet. 2020;395(10223):514–52. DOI:10.1016/S0140-6736(20)30154-9.; Levi M., van der Poll T. A short contemporary history of disseminated intravascular coagulation. Semin Thromb Hemost. 2014;40(8):874– 80. DOI:10.1055/s-0034-1395155.; Boral B., Williams D., Boral L. Disseminated intravascular coagulation. Am J Clin Pathol. 2016;146(6):670–80. DOI:10.1093/ajcp/aqw195.; Vaught A. J. Critical care for the obstetrician and gynecologist: obstetric hemorrhage and disseminated intravascular coagulopathy. Obstet Gynecol Clin North Am. 2016;43(4):611–22. DOI:10.1016/j.ogc.2016.07.006.; Levi M. Pathogenesis and diagnosis of disseminated intravascular coagulation. Int J Lab Hematol. 2018;40(Suppl 1):15–20. DOI:10.1111/ijlh.12830.; Moellering R.C., Abbott G. F., Ferraro M. J. Case records of the Massachussets General Hospital. Case 2–2011. A 30-year-old woman with shock after treatment for a furuncle. N Engl J Med. 2011;364(3):266–75. DOI:10.1056/NEJMcpc1003886.; Russell J.A. Management of sepsis. N Engl J Med. 2006;355(16):1699–713. DOI:10.1056/NEJMra043632.; Huang C., Wang Y., Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. DOI:10.1016/S0140-6736(20)30183-5.; Guan W.J., Ni Z.Y., Hu Y. et al; China Medical Treatment Expert Group for COVID-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020 Feb 28. DOI:10.1056/NEJMoa2002032. [Epub ahead of print].; Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844–7. DOI:10.1111/jth.14768.; Brun-Buisson C., Doyon F., Carlet J. et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA. 1995;274(12):968–74.; Vanderschueren S., De Weerdt A., Malbrain M. et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med. 2000;28(6):1871–6. DOI:10.1097/00003246-200006000-00031.; Lippi G., Plebani M., Henry B.M. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta. 2020;506:145–8. DOI:10.1016/j.cca.2020.03.022.; Wada H., Thachil J., Di Nisio M. et al; The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013;11:761–7. DOI:10.1111/jth.12155.; Taylor F. B., Toh C.H., Hoots W. K. et al; Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001;86(5):1327–30.; Levi M., Toh C.H., Thachil J., Watson H.G. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145(1):24–33. DOI:10.1111/j.1365-2141.2009.07600.x.; Di Nisio M., Baudo F., Cosmi B. et al; Italian Society for Thrombosis and Haemostasis. Diagnosis and treatment of disseminated intravascular coagulation: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res. 2012;129(5):e177–84. DOI:10.1016/j.thromres.2011.08.028.; Gando S., Levi M., Toh C.H. Disseminated intravascular coagulation. Nat Rev Dis Primers. 2016;2(1):16037. DOI:10.1038/nrdp.2016.38.; Ito T. PAMPs and DAMPs as triggers for DIC. J Intensive Care. 2014;2(1):67. DOI:10.1186/s40560-014-0065-0.; Tang N., Bai H., Chen X. et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020. Mar 27. DOI:10.1111/jth.14817. [Epub ahead of print].; Iba T., Nisio M.D., Levy J.H. et al. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open. 2017;7(9):e017046. DOI:10.1136/bmjopen-2017-017046.; Poterucha T. J., Libby P., Goldhaber S.Z. More than an anticoagulant: Do heparins have direct anti-inflammatory effects? Thromb Haemost. 2017;117(3):437–44. DOI:10.1160/TH16-08-0620.; https://www.gynecology.su/jour/article/view/633

الاتاحة: https://www.gynecology.su/jour/article/view/633
https://doi.org/10.17749/2313-7347.132

المؤلفون: I. Yavelov S., И. Явелов С.

المصدر: Meditsinskiy sovet = Medical Council; № 14 (2020); 48-54 ; Медицинский Совет; № 14 (2020); 48-54 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: atrial fibrillation, nonvalvular atrial fibrillation, venous thromboembolic complications, deep vein thrombosis, pulmonary embolism, bleeding, apixaban, vitamin K antagonists, warfarin, low-molecular-weight heparin, фибрилляция предсердий, неклапанная фибрилляция предсердий, венозные тромбоэмболические осложнения, тромбоз глубоких вен, тромбоэмболия легочных артерий, кровотечения, апиксабан, антагонисты витамина К, варфарин, низкомолекулярный гепарин

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5811/5302; Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europ J Cardio-Thoracic Surg. 2016;50(5):e1-e88. doi:10.1093/ejcts/ezw313.; Kearon C., Akl E.A., Ornelas J., Blaivas A., Jimenez B., Bounameaux H. et al. Antithrombotic Therapy for VTE Disease. CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026.; Konstantinides S., Meyer G., Becattini C., Bueno H., Geersing G.-J., Harjola V-P. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): The Task Force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC). Eur Heart J. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405.; Granger C.B., Alexander J.H., McMurray JJ., Lopes R.D., Hylek E.M., Hanna M. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992. doi:10.1056/NEJMoa1107039.; Hylek E.M., Held C., Alexander J.H., Lopes R.D., De Caterina R., Woidyla D.M. et al. Major Bleeding in Patients with Atrial Fibrillation Receiving Apixaban or Warfarin: the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. JACC. 2014;63(20):2141-2147. doi:10.1016/j.jacc.2014.02.549.; Hohnloser S.H., Hijazi Z., Thomas L., Alexander J.H., Amerena J., Hanna M. et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33(22):2821-2830. doi:10.1093/eurheartj/ehs274.; Lopes R.D., Al-Khatib S.M., Wallentin L., Yang H., Ansell J., Bahit M.C. et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial. Lancet. 2012;380(9855):1749-1758. doi:10.1016/S0140-6736(12)60986-6.; Wallentin L., Lopes R.D., Hanna M., Thomas L., Hellkamp A., Nepal S. et al. Efficacy and safety of apixaban compared with warfarin in different levels of predicted INR control for stroke prevention in atrial fibrillation. Circulation. 2013:127(22):2166-2176. doi:10.1161/CIRCULATIONAHA.112.142158.; Focks JJ., Brouwer M.A., Wojdyla D.M., Thomas L., Lopes R.D., Washam J.B. et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016;353:i2868. doi:10.1136/bmj.i2868.; Rao M.P., Vinereanu D., Wojdyla D.M., Alexander J.H., Atar D., Hylek E.M. et al. Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights from the ARISTOTLE Trial. Am J Med. 2018;131(3):269-275. doi:10.1016/j.amjmed.2017.10.036.; Alexander J.H., Andersson U., Lopes R.D., Hijazi Z., Hohnloser S.H., Ezekowitz J.A. et al. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine. A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2016;1(6):673-681. doi:10.1001/jamacardio.2016.1829.; Bahit M.C., Lopes R.D., Wojdyla D.M., Held C., Hanna M., Vinereanu D. et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart. 2017;103(8):623-628. doi:10.1136/heartjnl-2016-309901.; Lopes R.D., Heizer G., Aronson R., Vora A.N., Massaro T., Mehran R. et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380:1509-1524. doi:10.1056/NEJMoa1817083.; Windecker S., Lopes R.D., Massaro T., Jones-Burton C., Granger C.B., Aronson R. et al. Antithrombotic Therapy in Patients with Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or with Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention. Circulation. 2019;140(23):1921-1932. doi:10.1161/CIRCULATIONAHA.119.043308.; Vora A.N., Alexander J.H., Wojdyla D., Aronson R., Granger C.B., Darius H. et al. Hospitalization among Patients with Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated with Apixaban or Aspirin. Circulation. 2019;140(23):1960-1963. doi:10.1161/CIRCULATIONAHA.119.043754.; Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Johnson M. et al. Oral Apixaban for the Treatment of Acute Venous Thromboembolism. N Engl J Med. 2013;369:799-808. doi:10.1056/NEJMoa1302507.; Raskob G.E., Gallus A.S., Sanders P., Thompson J.R., Agnelli G., Buller H.R. et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. Thromb Haemost. 2016;115(04):809-816. doi:10.1160AH15-09-0752.; Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Johnson M. et al. Apixaban for Extended Treatment of Venous Thromboembolism. N Engl J Med. 2013;368:699-708. doi:10.1056/NEJMoa1207541.; Agnelli G., Becattini C., Meyer G., Munoz A., Huisman M.V., Connors J.M. et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020;382:1599-1607. doi:10.1056/NEJMoa1915103.; https://www.med-sovet.pro/jour/article/view/5811

الاتاحة: https://www.med-sovet.pro/jour/article/view/5811
https://doi.org/10.21518/2079-701X-2020-14-48-54

المؤلفون: A. D. Makatsariya, A. V. Vorobyov

المصدر: Медицинский совет, Vol 0, Iss 2, Pp 79-85 (2016)

مصطلحات موضوعية: низкомолекулярный гепарин, пероральные антикоагулянты, гепарин-индуцированная тромбоцитопения профилактика тромбозов, ингибиторы xa-фактора, low molecular weight heparin, oral anticoagulants, heparin-induced thrombocytopenia, thrombosis prophylaxis, fact, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/45; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/b961a93b89ed4f25a128fd7b8560eca3

المؤلفون: M. D. Dibirov, A. H. Magdiev

المصدر: Амбулаторная хирургия, Vol 0, Iss 3-4, Pp 69-76 (2016)

مصطلحات موضوعية: тромбоз, диагностика, тромбоэмболия легочной артерии, лечение, низкомолекулярный гепарин, цибор, thrombosis, diagnostics, pulmonary artery thromboembolia, low-molecular heparin, zibor, Surgery, RD1-811

وصف الملف: electronic resource

Relation: https://www.a-surgeon.ru/jour/article/view/63; https://doaj.org/toc/2712-8741; https://doaj.org/toc/2782-2591

URL الوصول: https://doaj.org/article/431964b91a2a46f98078168105e91126

المؤلفون: V. B. Zubenko, В. Б. Зубенко

المصدر: Obstetrics, Gynecology and Reproduction; Vol 12, No 1 (2018); 17-22 ; Акушерство, Гинекология и Репродукция; Vol 12, No 1 (2018); 17-22 ; 2500-3194 ; 2313-7347

مصطلحات موضوعية: ведение беременности, thrombophilia, hemostasis disorders, prevention of pregnancy complications, low molecular weight heparin, pregnancy management, тромбофилия, нарушения гемостаза, профилактика осложнений беременности, низкомолекулярный гепарин

وصف الملف: application/pdf

Relation: https://www.gynecology.su/jour/article/view/466/659; Медянникова И.В. Особенности течения беременности и родов при аномалиях плацентации. Вестник Кузбасского научного центра. 2007; 4: 86-7.; Coulam C.B., Jeyendran R.S., Fishel L.A., Roussev R. Multiple thrombophilic gene mutations are risk factors for implantation failure. Reprod Biomed Online. 2006; 12 (3): 322 7.; Медянникова И.В. Акушерские и перинатальные аспекты аномальной плацентации: Автореф. дис. канд. мед. наук. Пермь. 2007: 23 с.; Бицадзе В.О. Патогенез, принципы диагностики и профилактики осложнений беременности, обусловленных тромбофилией: Автореф. дис. докт. мед. наук. М. 2004: 46 с.; Макацария А.Д., Бицадзе В.О. Тромбофилии и противотромботическая терапия в акушерской практике. М.: Триада-Х. 2003: 904 с.; Макацария А.Д., Бицадзе В.О., Акиньшина С.В. Тромбозы и тромбоэмболии в акушерско- гинекологической клинике: молекулярногенетические механизмы и стратегия профилактики тромбоэмболических осложнений: руководство для врачей. М.: МИА. 2007: 1064 с.; Qublan H., Amarin Z., Dabbas M. et al. Low-molecular-weight heparin in the treatment of recurrent IVF-ET failure and thrombophilia: a prospective randomized placebo-controlled trial. Hum Fertil (Camb). 2008; 11: 246-53.; Achache H., Revel A. Endometrial receptivity markers, the journey to successful embryo implantation. Hum Reprod Updatе. 2006; 12 (6): 731-46.; Azem F., Many A., Ben Ami I. et al. Increased rates of thrombophilia in women with repeated IVF failures. Hum Reprod. 2004; 19: 368-70.; Berker B., Taskin S., Kahraman K., Taskin E.A., Atabekoglu C., Sonmezer M. The role of low-molecular-weight heparin in recurrent implantation failure: a prospective, quasirandomized, controlled study. Fertil Steril. 2011; 95 (8): 2499-502.; Assou S., Boumela I., Haouzi D. et al. Dynamic changes in gene expression during human early embryo development: from fundamental aspects to clinical applications. Hum Reprod Updatе. 2011; 17 (2): 272-90.; Баймурадова С.М. Патогенез, принципы диагностики, профилактики и терапии синдрома потери плода, обусловленного приобретенными и генетическими дефектами гемостаза: Автореф. дис. докт. мед. наук. М. 2007: 46 с.; Redline R.W. Thrombophilia and placental pathology. Clin Obstet Gynecol. 2006; 49 (4): 885-94.; Gogia N., Machin G.A. Maternal thrombophilias are associated with specific placental lesions. Pediatr Dev Pathol. 2008; 11 (6): 424-9.; https://www.gynecology.su/jour/article/view/466

الاتاحة: https://www.gynecology.su/jour/article/view/466
https://doi.org/10.17749/2313-7347.2018.12.1.017-022

المؤلفون: E. V. Moroz, E. N. Artemkin, E. V. Kryukov, V. A. Chernetsov, Е. В. Мороз, Э. Н. Артемкин, Е. В. Крюков, В. А. Чернецов

المصدر: General Reanimatology; Том 14, № 3 (2018); 15-26 ; Общая реаниматология; Том 14, № 3 (2018); 15-26 ; 2411-7110 ; 1813-9779 ; 10.15360/1813-9779-2018-3

مصطلحات موضوعية: низкомолекулярный гепарин, digestive system, bleeding, erosive esophagitis, erosions, ulcers, H.pylori, risk factors, antithrombotic therapy, aspirin, warfarin, clopidogrel, dabigatran, rivaroxaban, low-molecular heparin, пищеварительная система, кровотечения, эрозивный эзофагит, эрозии, язвы, факторы риска, антитромботическая терапия, аспирин, варфарин, клопидагрел, дабигатран, ривароксабан

وصف الملف: application/pdf

Relation: https://www.reanimatology.com/rmt/article/view/1687/1219; https://www.reanimatology.com/rmt/article/view/1687/1220; Мороз Е.В., Каратеев А.Е., Крюков Е.В., Чернецов В.А. Желудочнокишечные кровотечения при использовании новых пероральных антикоагулянтов: эпидемиология, факторы риска, лечение и профилактика. Науч.-практ. ревматология. 2017; 55 (6): 675-684. DOI:10.14412/1995-4484-2017-675-684; Weitz J.I., Jaffer I.H., Fredenburgh J.C. Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants. F1000Res. 2017; 6: 985. DOI:10.12688/f1000research.11174.1. PMID: 28713563; Deutsch D., Boustière C., Ferrari E., Albaladejo P., Morange P.E., Benamouzig R. Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. Therap. Adv. Gastroenterol. 2017; 10 (6): 495-505. DOI:10.1177/1756283X17702092. PMID: 28567119; Hsu P.I., Tsai T.J. Epidemiology of upper gastrointestinal damage associated with low-dose aspirin. Curr. Pharm. Des. 2015; 21 (35): 5049-5055. DOI:10.2174/1381612821666150915104800. PMID: 26369688; Cheung K.S., Leung W.K. Gastrointestinal bleeding in patients on novel oral anticoagulants: risk, prevention and management. World J. Gastroenterol. 2017; 23 (11): 1954-1963. DOI:10.3748/wjg.v23.i11.1954. PMID: 28373761; Eikelboom J.W., Wallentin L., Connolly S.J., Ezekowitz M., Healey J.S., Oldgren J., Yang S., Alings M., Kaatz S., Hohnloser S.H., Diener H.C., Franzosi M.G., Huber K., Reilly P., Varrone J., Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011; 123 (21): 2363-2372. DOI:10.1161/CIRCULATIONAHA.110.004747. PMID: 21576658; Здравоохранение в России. 2017. Статистический сборник Росстата. М.; 2017: 170.; Загородний Н.В. Некоторые статистические данные об эндопротезировании тазобедренного и коленного суставов в РФ за 2014–2015 годы. Лидер мнений. 2017; 3: 12-18.; Thomopoulos K.C., Mimidis K.P., Theocharis G.J., Gatopoulou A.G., Kartalis G.N., Nikolopoulou V.N. Acute upper gastrointestinal bleeding in patients on long-term oral anticoagulation therapy: endoscopic findings, clinical management and outcome. World J. Gastroenterol. 2005; 11 (9): 1365-1368. DOI:10.3748/wjg.v11.i9.1365. PMID: 15761977; Rubin T.A., Murdoch M., Nelson D.B. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointest. Endosc. 2003; 58 (3): 369-373. DOI:10.1067/S0016-5107(03) 00010-5. PMID: 14528210; Каратеев А.Е., Насонова В.А. Развитие и рецидивирование язв желудка и двенадцатиперстной кишки у больных, принимающих нестероидные противовоспалительные препараты: влияние стандартных факторов риска. Тер. архив. 2008; 80 (5): 62–66. PMID: 18590118; Каратеев А.Е. Лечение бисфосфанатами и патология пищевода. Совр. ревматология. 2010; 3: 73-79.; Wood M., Shaw P. Pradaxa-induced esophageal ulcer. BMJ Case Rep. 2015; 2015: pii: bcr2015211371. DOI:10.1136/bcr-2015-211371. PMID: 26452739; Singh S., Savage L., Klein M., Thomas C. Severe necrotic oesophageal and gastric ulceration associated with dabigatran. BMJ Case Rep. 2013; 2013: pii: bcr2013009139. DOI:10.1136/bcr-2013-009139. PMID: 23608859; Izumikawa K., Inaba T., Mizukawa S., Kawai Y., Sakakihara I., Ishikawa S., Miyoshi M., Wato M., Kawai K. Two cases of dabigatran-induced esophageal ulcer indicating the usefulness of drug administration guidance. Nihon Shokakibyo Gakkai Zasshi. 2014; 111 (6): 1096-1104. PMID: 24898488; Scheppach W., Meesmann M. Exfoliative esophagitis while taking dabigatran. Dtsch. Med. Wochenschr. 2015; 140 (7): 515-518. DOI:10.1055/s-0041-101313. PMID: 25826037; Okada M., Okada K. Exfoliative esophagitis and esophageal ulcer induced by dabigatran. Endoscopy. 2012; 44 Suppl 2 UCTN: E23-E24. DOI:10.1055/s-0031-1291503. PMID: 22396259; Toya Y., Nakamura S., Tomita K., Matsuda N., Abe K., Abiko Y., Orikasa S., Akasaka R., Chiba T., Uesugi N., Sugai T., Matsumoto T. Dabigatraninduced esophagitis: the prevalence and endoscopic characteristics. J. Gastroenterol. Hepatol. 2016; 31 (3): 610-614. DOI:10.1111/jgh.13024. PMID: 26102078; Vicente V., Martín A., Lecumberri R., Coll-Vinent B., Suero C., GonzálezPorras J.R., Marco P., Mateo J., Roldán V., Soulard S., Crespo C., Camats M.; Grupo DECOVER. Clinical perspectives on the management of bleeding in patients on oral anticoagulants: the DECOVER Study (DElphi Consensus on oral COagulation and therapy action reVERsal). Emergencias. 2017; 29 (1): 18-26. PMID: 28825264; Lanas-Gimeno A., Lanas A. Risk of gastrointestinal bleeding during anticoagulant treatment. Expert Opin. Drug Saf. 2017; 16 (6): 673-685. DOI:10.1080/14740338.2017.1325870. PMID: 28467190; Albaladejo P., Samama C.M., Sié P., Kauffmann S., Mémier V., Suchon P., Viallon A., David J.S., Gruel Y., Bellamy L., de Maistre E., Romegoux P., Thoret S., Pernod G., Bosson J.L.; GIHP-NACO Study Group. Management of severe bleeding in patients treated with direct oral anticoagulants: an observational registry analysis. Anesthesiology. 2017; 127 (1): 111-120. DOI:10.1097/ALN.0000000000001631. PMID: 28410272; Lauffenburger J.C., Rhoney D.H., Farley J.F., Gehi A.K., Fang G. Predictors of gastrointestinal bleeding among patients with atrial fibrillation after initiating dabigatran therapy. Pharmacotherapy. 2015; 35 (6): 560-568. DOI:10.1002/phar.1597. PMID: 26044889; Каратеев А.Е., Цурган А.В., Мороз Е.В. Helicobacter pylori у больных ревматическими заболеваниями: частота инфицированности и оценка эффективности альтернативной схемы эрадикационной терапии. РМЖ. 2017; 25 (17): 1220-1224.; Каратеев А.Е., Мороз Е.В., Цурган А.В., Гонтаренко Н.В. Нужно ли проводить эрадикацию Helicobacter pylori у больных с эрозиями и язвами, возникшими на фоне терапии нестероидными противовоспалительными препаратами? Рос. журн. гастроэнтерол., гепатол., колопроктол. 2016; 26 (6): 5-17. DOI:10.22416/1382-4376-2016-6-5-17; Andersen I.B., Jørgensen T., Bonnevie O., Grønbaek M., Sørensen T.I. Smoking and alcohol intake as risk factors for bleeding and perforated peptic ulcers: a population-based cohort study. Epidemiology. 2000; 11 (4): 434-439. DOI:10.1097/00001648-200007000-00012. PMID: 10874551; Kang J.M., Kim N., Lee B.H., Park H.K., Jo H.J., Shin C.M., Lee S.H., Park Y.S., Hwang J.H., Kim J.W., Jeong S.H., Lee D.H., Jung H.C., Song I.S. Risk factors for peptic ulcer bleeding in terms of Helicobacter pylori, NSAIDs, and antiplatelet agents. Scand. J. Gastroenterol. 2011; 46 (11): 1295-1301. DOI:10.3109/00365521.2011.605468. PMID: 21815866; Strate L.L., Singh P., Boylan M.R., Piawah S., Cao Y., Chan A.T. A prospective study of alcohol consumption and smoking and the risk of major gastrointestinal bleeding in men. PLoS One. 2016; 11 (11): e0165278. DOI:10.1371/journal.pone.0165278. PMID: 27824864.; https://www.reanimatology.com/rmt/article/view/1687

الاتاحة: https://www.reanimatology.com/rmt/article/view/1687
https://doi.org/10.15360/1813-9779-2018-3-15-26

المؤلفون: S. V. Akinshina, A. D. Makatsaria, V. O. Bitsadze

المصدر: Медицинский совет, Vol 0, Iss 9, Pp 84-89 (2014)

مصطلحات موضوعية: репродуктивные технологии, тромбоэм-болические осложнения, профилактика, низкомолекулярный гепарин, бемипарин, reproductive technologies, thromboembolic complications, prevention, low-molecular-weight heparin, bemiparin, Medicine

وصف الملف: electronic resource

Relation: https://www.med-sovet.pro/jour/article/view/637; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790

URL الوصول: https://doaj.org/article/ded306ff5996435ba82f5a47698e6abc

المؤلفون: G. Totchiev F., F. Tarek, Г. Тотчиев Ф., Ф. Тарек

المصدر: Meditsinskiy sovet = Medical Council; № 2 (2017); 142-144 ; Медицинский Совет; № 2 (2017); 142-144 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-2

مصطلحات موضوعية: venous thromboembolic complications, deep vein thrombosis, low molecular weight heparin, bemiparin sodium, венозные тромбоэмболические осложнения, тромбоз глубоких вен, низкомолекулярный гепарин, бемипарин натрия

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1739/1685; Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО). Флебология, 2015, 4(выпуск 2).; McLean K, Cushman M. Venous thromboembolism and stroke in pregnancy. Hematology Am Soc Hematol Educ Program, 2016 Dec 2, 2016(1): 243-250.; Kamel H, Navi BB, Sriram N, Hovsepian DA, Devereux RB, Elkind MS. Risk of a thrombotic event after the 6-week postpartum period. Engl J Med., 2014 Apr 3, 370(14): 1307-15.; Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium. Green-top Guideline, 2015 April, 37a.; Navarro-Quilis A et al. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. J. Thromb. Haemost., 2003, 1(3): 425-32.; https://www.med-sovet.pro/jour/article/view/1739

الاتاحة: https://www.med-sovet.pro/jour/article/view/1739
https://doi.org/10.21518/2079-701X-2017-2-142-144

المؤلفون: L. A. Ozolinya, N. R. Ovsepyan, Л. А. Озолиня, Н. Р. Овсепян

المصدر: Meditsinskiy sovet = Medical Council; № 13 (2017); 110-117 ; Медицинский Совет; № 13 (2017); 110-117 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2017-13

مصطلحات موضوعية: привычное невынашивание беременности, хроническая вирусная инфекция, гиперкоагуляция, тромбофилия, низкомолекулярный гепарин, эноксапарин натрия, дипиридамол, chronic viral infection, hypercoagulation, thrombophilia, low-molecular heparin, sodium enoxaparine, dipyridamol

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/1993/1976; Акушерство. Национальное руководство под редакцией Г.М. Савельевой, Г.Т. Сухих, В.Н. Серова, В.Е. Радзинского. 2-е изд., перераб. и доп. М.: изд. группа «ГЭОТАР-Медиа», 2015. 57, 180-212.; Клинические рекомендации. Акушерство и гинекология. 4-е изд., перераб. и доп. М.: изд. группа «ГЭОТАР-Медиа», 2014. с. 51-1044, с. 216.; Елисеева М.Ю., Мынбаев О.А., Масихин К.Н. Современные взгляды на герпетическую инфекцию. Проблемы репродукции, 2009, 15(1): 25-35.; Ершов Ф.И., Наровлянский А.И., Мезенцева М.В. Ранние цитокиновые реакции при вирусных инфекциях. Цитокины и воспаление, 2004, 3(1): 1-6.; Макацария А.Д., Долгушина Н.В. Герпетическая инфекция. Антифосфолипидный синдром и синдром потери плода. Изд-во «Триада-Х». М., 2004. 80с.; Выкидыш в ранние сроки беременности: диагностика и тактика ведения. Клинические рекомендации (Протокол лечения). М., 2016. 32 с.; Профилактика венозных тромбоэмболических осложнений в акушерстве и гинекологии. Клинические рекомендации (Протокол). М., 2014. 32с.; Singh M, Chaudhry P, Asselin E. Bridging endometrial receptivity and implantation network of hormones, cytokines, and growth factors. J. Endocrinol., 2011, 210: 5-14.; Alijotas-Reig J, Garrido-Gimenez C. Current concepts and new trends in the diagnosis and management of recurrent miscarriage. Obstet. Gynecol. Surv., 2013, 68(6): 445-466.; Fitzgibbon J, Morrison JJ, Smith TJ et al. Modulation of human uterine smooth muscle cell collagen contractivity by thrombin, Y-27632, TNF-α and indomethacin. Reprod. Biol. Endocrinol., 2009, 10: 1186.; Зайнулина М.С., Корнюшина Е.А., Бикмуллина Д.Р. Тромбофилия: этиологический фактор или патогенетический аспект осложненного течения беременности? Журнал акушерства и женских болезней, 2010, LIX(1): 18-30.; Макацария А.Д., Пшеничникова Е.Б., Пшеничникова Т.Б., Бицадзе В.О. Метаболический синдром и тромбофилия в акушерстве и гинекологии. М.: МИА, 2006. 470с.; Сидельникова В.М., Сухих Г.Т. Невынашивание беременности. М.: МИА, 2010. 536 с.; Юдаев В.Н., Серова О.Ф., Трифонова И.А. и др. Роль хронического эндометрита в генезе ранних репродуктивных потерь. Вестник последипломного медицинского образования, 2010, 1: 36-38.; Инструкция по применению клексана. Доступно 15.06.17. по: https://www.vidal.ru/ drugs/clexane_9446.; Visser J., Ulander VM, Helmerhorst FM et al. Thromboprophylaxis for recurrent miscarrige in women with or without thrombophilia. HABENOX: A randomized multicentre trial. Thromb. Haemostasis., 2011, 105: 295-301.; Инструкция по применению курантила. Доступно 15.06.17. по: https:// www.vidal.ru/ drugs/curantyl n 25_428.; Sater MS, Finam RR, Abu-Hijleh FM et al. Antiphosphatidylserine, anti-cardiolipin, anti-β2 glycoprotein 1 and anti-prothrombin antibodies in recurrent miscarriage at 8-12 gestation weeks. Eur. J. obstet. Gynecol. Reprod. Biol., 2012, 163: 170-174.; Громова О.А., Лиманова О.А., Торшин И.Ю., Керимкулова Н.В., Рудаков К.В. Дозозависимость защитных эффектов фолиевой кислоты в прегравидарный период, во время беременности и в период лактации. РМЖ, 2014, 22(1): 27-34.; Озолиня Л.А., Кашежева А.З. Прегравидарная подготовка женщин с гипергомоцистеинемией. Гинекология, 2013, 2: 67-70.; Приказ Министерства здравоохранения России от 01.11.2012 №572н «Об утверждении Порядка оказания медицинской помощи по профилю «акушерство и гинекология (за исключением использования вспомогательных репродуктивных технологий)» №572, с.46. Доступно 15.06.17. по: https:// www.base. garant.ru / 70352632.; Стуров В.Г. Стратегия фолатной профилактики репродуктивных потерь: от прегравидарной подготовки к рациональному ведению беременности. Тезисы III Общероссийской конференции «Перинатальная медицина: от прегравидарной подготовки к здоровому материнству и детству» (9-11 февраля 2017 г., г. Санкт-Петербург). М.: Status Praesens, 2017: 68-69.; Громова О.А., Серов В.Н., Торшин И.Ю. Магний в акушерстве и гинекологии: история применения и современные взгляды. Трудный пациент, 2008, 8: 10–15.; Дефицит магния в акушерстве и гинекологии: результаты национального совещания. Акушерство. Гинекология. Репродукция, 2014, 8(2): 6-10.; Зырянов С.К. и соавт. Терапевтический Архив 2016; 12: 119-125; https://www.med-sovet.pro/jour/article/view/1993

الاتاحة: https://www.med-sovet.pro/jour/article/view/1993
https://doi.org/10.21518/2079-701X-2017-13-110-117

المؤلفون: S. Akinshina V., A. Makatsariya D., V. Bitsadze O., N. Stuleva S., T. Mashkova Ya., С. Акиньшина В., А. Макацария Д., В. Бицадзе О., Н. Стулева С., Т. Машкова Я.

المصدر: Obstetrics, Gynecology and Reproduction; Vol 8, No 2 (2014); 89-96 ; Акушерство, Гинекология и Репродукция; Vol 8, No 2 (2014); 89-96 ; 2500-3194 ; 2313-7347

مصطلحات موضوعية: venous thromboembolism, ovarian hyperstimulation syndrome, a genetic thrombophilia, antiphospholipid syndrome, low molecular weight heparin, ВЕНОЗНАЯ ТРОМБОЭМБОЛИЯ, СИНДРОМ ГИПЕРСТИМУЛЯЦИИ ЯИЧНИКОВ, ГЕНЕТИЧЕСКАЯ ТРОМБОФИЛИЯ, АНТИФОСФОЛИПИДНЫЙ СИНДРОМ, НИЗКОМОЛЕКУЛЯРНЫЙ ГЕПАРИН

وصف الملف: application/pdf

Relation: https://www.gynecology.su/jour/article/view/69/70; Бицадзе В.О. Патогенез, принципы диагностики и профилактики осложнений беременности, обусловленных тромбофилией. Дис. . докт. мед. наук. М. 2004; 251 с.; Albert C., Garrido N., Mercader A., Rao C.V., Remohí J., Simón C., Pellicer A. The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome. Mol Hum Reprod. 2002 May; 8 (5): 409-18.; Avecillas J.F., Falcone T., Arroliga A.C. Ovarian hyperstimulation syndrome. Crit. Care Clin. 2004 Oct; 20 (4): 679-95.; Bates S.M., Greer I.A., Middeldorp S., Veenstra D.L., Prabulos A.M., Vandvik P.O. American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis. 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 141 (2 Suppl): e691S-736S.; Chan W.S., Ginsberg J.S. A review of upper extremity deep vein thrombosis in pregnancy: unmasking the 'ART' behind the clot. J. Thromb. Haemost. 2006 Aug; 4 (8): 1673-7.; Cluroe A.D., Synek B.J. A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology. 1995 Oct; 27 (4): 344-6.; Colazingari S., Treglia M., Najjar R., Bevilacqua A. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch. Gynecol. Obstet. 2013 May 25.; Delvigne A., Rozenberg S. Systematic review of data concerning etiopathology of ovarian hyperstimulation syndrome. Int. J. Fertil. Womens Med. 2002 Sep-Oct; 47 (5): 211-26.; Dulitzky M., Cohen S.B., Inbal A., Seidman D.S., Soriano D., Lidor A., Mashiach S.,Rabinovici J. Increased prevalence of thrombophilia among women with severe ovarian hyperstimulation syndrome. Fertil Steril. 2002 Mar; 77 (3): 463-7.; Enskog A., Henriksson M., Unander M., Nilsson L., Brannstrom M. Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 1999 May; 71 (5): 808-14.; Felberbaum R.E., Diedrich K. Gonadotrophinreleasing hormone antagonists: will they replace the agonists? Reprod. Biomed. Online. 2003 Jan-Feb; 6 (1): 43-53.; Gerli S., Papaleo E., Ferrari A., Di Renzo G.C. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur. Rev. Med. Pharmacol. Sci. 2007; 11 (5): 347-354.; Kodama H., Fukuda J., Karube H., Matsui T., Shimizu Y., Tanaka T. Status of the coagulation and fibrinolytic systems in ovarian hyperstimulation syndrome. Fertil. Steril. 1996 Sep; 66 (3): 417-24.; Nelson S.M., Greer I.A. The potential role of heparin in assisted conception. Hum. Reprod. Update. 2008 Nov-Dec; 14 (6): 623-45.; Ou Y.C., Kao Y.L., Lai S.L., Kung F.T., Huang F.J., Chang S.Y., ChangChien C.C. Thromboembolism after ovarian stimulation: successful management of a woman with superior sagittal sinus thrombosis after IVF and embryo transfer: case report. Hum. Reprod. 2003 Nov; 18 (11): 2375-81.; Qublan H.S., Eid S.S., Ababneh H.A., Amarin Z.O., Smadi A.Z., Al-Khafaji F.F., Khader Y.S. Acquired and inherited thrombophilia: implication in recurrent IVF and embryo transfer failure. Hum. Reprod. 2006 Oct; 21 (10): 2694-8.; Rao A.K., Chitkara U., Milki A.A. Subclavian vein thrombosis following IVF and ovarian hyperstimulation: a case report. Hum. Reprod. 2005 Dec; 20 (12): 3307-12.; Ricci G., Cerneca F., Simeone R., Pozzobon C., Guarnieri S., Sartore A., Pregazzi R., Guaschino S. Impact of highly purified urinary FSH and recombinant FSH on haemostasis: an openlabel, randomized, controlled trial. Hum Reprod. 2004 Apr; 19 (4): 838-48.; Rizk B., Aboulghar M., Smitz J., Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update. 1997 May-Jun; 3 (3): 255-66.; Rogolino A., Coccia M.E., Fedi S., Gori A.M., Cellai A.P., Scarselli G.F., Prisco D., Abbate R. Hypercoagulability, high tissue factor and low tissue factor pathway inhibitor levels in severe ovarian hyperstimulation syndrome: possible association with clinical outcome. Blood. Coagul. Fibrinolysis. 2003 Apr; 14 (3): 277-82.; Yan Z., Weich H.A., Bernart W., Breckwoldt M., Neulen J. Vascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro. J. Clin. Endocrinol. Metab. 1993 Dec; 77 (6): 1723-5.; Yoshii F., Ooki N., Shinohara Y., Uehara K., Mochimaru F. Multiple cerebral infarctions associated with ovarian hyperstimulation syndrome. Neurology. 1999 Jul 13; 53 (1): 225-7.; https://www.gynecology.su/jour/article/view/69

الاتاحة: https://www.gynecology.su/jour/article/view/69

المؤلفون: N. Stuleva S., Н. Стулёва С.

المصدر: Obstetrics, Gynecology and Reproduction; Vol 10, No 3 (2016); 70-74 ; Акушерство, Гинекология и Репродукция; Vol 10, No 3 (2016); 70-74 ; 2500-3194 ; 2313-7347 ; 10.17749/2313-7347.2016.10.2

مصطلحات موضوعية: thrombophilia, IVF implantation failure, antiphospholipid antibodies, in-vitro fertilization, assisted reproductive technology, antiphospholipid syndrome, hyperhomocysteinemia, thrombosis of venous sinuses, экстракорпоральное оплодотворение (ЭКО), тромбофилия, антифосфолипидные антитела, низкомолекулярный гепарин, тромбоз венозных синусов, гипергомоцистеинемия, синдром гиперстимуляции яичников

وصف الملف: application/pdf

Relation: https://www.gynecology.su/jour/article/view/348/559; Бицадзе В.О., Акиньшина С.В., Хизроева Д.Х., Макацария А.Д., Стулёва Н.С., Машкова Т.Я. Тромбофилия и тромбоэмболические осложнения, связанные с использованием вспомогательных репродуктивных технологий. Акушерство, гинекология и репродукция. 2014; 8 (2): 89-96.; Профилактика повторных осложнений беременности в условиях тромбофилии. Руководство для врачей. Под. ред. А.Д. Макацария, В.О. Бицадзе. М. 2015.; Беременность высокого риска. Руководство для врачей. Под. ред. А.Д. Макацария, Ф. Червенак, В.О. Бицадзе. М. 2015.; Макацария Н.А., Хизроева Д.Х., Бицадзе В.О., Стулёва Н.С., Машкова Т.М., Абрамян Р.Р. Антифосфолипидные антитела у пациенток с неудачами ЭКО. Акушерство, гинекология и репродукция. 2014; 8 (4): 93.; Стулёва Н.С., Абрамян Р.Р., Селхаджиева М.С. Спектр антифосфолипидных антител у пациенток с синдромом потери плода. Акушерство, гинекология и репродукция. 2014; 8 (4): 84.; Хизроева Д.Х., Стулёва Н.С., Михайлиди И. Значение определения протеина С в акушерской практике. Практическая медицина. 2013; 7 (17): 52-57.; Хизроева Д.Х., Стулёва Н.С., Машкова Т.М., Абрамян Р.Р. Циркуляция антифосфолипидных антител и неудачи ЭКО. Акушерство, гинекология и репродукция. 2015; 9 (3): 6-10.; Brenner B. Haemostatic changes in pregnancy. Thromb. Res. 2004; 114 (5-6): 409-414.; Frankline R.D., Kutteh W.H. Antiphospholipid antibodies (APA) and reccurent pregnancy loss: treating a unique APA positive population. Hum. Reprod. 2002; 17: 2981-2985.; Kovac M., Mitic G. et al. Thrombophilia in women with pregnancy-associated complications: fetal loss and pregnancyrelated venous thromboembolism. Gynecol. Obstet. Invest. 2010; 69 (4): 233-8.; Marcello de Nisio, Anne WS Rutjies, Noemi Ferrante,Gian Mario Tibony, Franco Cuccurullo, Ettore Porreca. Thrombophilia and outcomes of assisted reproduction technologies: a systematic review and meta-analysis. Blood. June 2011; 2670-78.; Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci PM. Hyperhomocysteinemiain cerebral vein thrombosis. Blood. 2003;102(4):1363-1366; Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med. 1998; 338 (25): 1793-1797. doi:1056/nejm199806183382502.; Mazhar S.B., Emanuel A. Haematological defects in recurrent pregnancy loss. Haematology Updates. 2011: 56-60.; Nelson S.M., Greer I.A. The potential role of heparin in assisted conception. Hum. Reprod. Update. 2008 Nov-Dec; 14 (6): 623-645.; Qublan H.S., Eid S.S., Ababneh H.A., Amarin Z.O., Smadi A.Z.,Al-Khafaji F.F., Khader Y.S.Acquired and inherited thrombophilia: implication in recurrent IVF and embryo transfer failure. Hum Reprod. 2006 Oct; 21 (10): 2694-8.; https://www.gynecology.su/jour/article/view/348

الاتاحة: https://www.gynecology.su/jour/article/view/348
https://doi.org/10.17749/2313-7347.2016.10.2.070-074